BioSyent Inc.

BioSyent Inc.

February 03, 2015 08:00 ET

BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System®

TORONTO, ONTARIO--(Marketwired - Feb. 3, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System® for pre-filled syringes (PFS), a new urgent care product for use in hospitals and acute care settings.

The Aguettant System® for PFS offers a patented innovation that can be used for a variety of injectable medications. The 2010 Pharmapack award winning1 ready-to-use Aguettant System® for PFS features a needleless, glassless, sterile plastic syringe with a dual tamper-evident seal. "We believe the unique features of the Aguettant System® can provide hospitals, health care professionals, and patients with a safer option for handling and administering injectables" said BioSyent CEO René Goehrum.

The Aguettant System® was in-licensed by BioSyent from Laboratoire Aguettant of Lyon, France for exclusive marketing and distribution in Canada. Aguettant has a more than 100 year history of providing innovative and patented infusion delivery systems to hospitals. The Aguettant System® for PFS has been available since 2009 and is used in several European countries including France, the UK and Belgium.

The initial product offering of the Aguettant System® contains atropine sulfate, a commonly used drug in emergency situations and anaesthetic procedures, and is the first of three drugs for use in urgent care that have been in-licensed from Laboratoire Aguettant.

"The launch of the Aguettant System® is yet another milestone in the development of the BioSyent Pharma business" commented René Goehrum, CEO of BioSyent. "The Aguettant System® for PFS with atropine sulfate is our sixth marketed pharmaceutical product and represents a further broadening of our portfolio. This will be a key product in our Hospital Business Unit."

The Aguettant System® for PFS with atropine sulfate is approved by Health Canada and is available for immediate shipping.

To learn more about the Aguettant System®, please visit the product website


The Company also wishes to announce that the Board of Directors has granted a total of 21,276 options to employees, consultants, directors and officers of BioSyent. The option grant is the result of BioSyent's annual compensation review and the issuance is made under the stock option plan of the Company approved by shareholders on June 10, 2014. The options will have an exercise price of $10.97 and are exercisable for a period of 10 years from the date of the grant.

In addition, the Board of Directors has approved the issuance of up to an additional 2,600 options under the stock option plan to be issued to future new employees and consultants of the Company. If granted, the vesting schedule and the exercise price of such options will be determined in accordance with the terms of the Company's stock option plan and the policies of the TSX Venture Exchange on the date of their grant.

About Laboratoire Aguettant

Aguettant is a fully integrated pharmaceutical company dedicated to the development and the commercialization of essential hospital medicines mainly in critical care, anaesthesiology, micro-nutrients and neurology.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,851,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact Information